Gilead’s new immunotherapy asset targets the TREX1 protein, which is a novel target in oncology.
Developed by UCL spinout Autolus, Aucatzyl will be launched imminently across England and Wales.
The long-term effect of Voyxact on kidney function decline in IgAN is yet to be established.
The agreement is projected to save $90m for Gavi and countries, equating to more than 30 million extra vaccine doses.
The partnership seeks to establish a manufacturing pathway to transition Cellergy’s therapy to clinical application.
The approval is supported by findings from the open-label Phase IIIb STRENGTH study and the Phase III STEER study.
